發送短信 : Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)

  ______     ___      _____      ___     _    _   
 /_   _//   / _ \\   /  ___||   / _ \\  | \  / || 
   | ||    / //\ \\ | // __    | / \ || |  \/  || 
  _| ||   |  ___  ||| \\_\ ||  | \_/ || | .  . || 
 /__//    |_||  |_|| \____//    \___//  |_|\/|_|| 
 `--`     `-`   `-`   `---`     `---`   `-`  `-`